Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Tina Tan
Regenerative medicine firm Tissue Regenix is now seeking a new CEO following the departure of Anthony Odell. The change in leadership comes two months after the company made its maiden M&A deal, acquiring CellRight Technologies.
With its coffers topped up and a new CEO in place, Lumicell is forging ahead with clinical trials of its LUM real-time, cancer imaging system, designed to improve the outcomes of surgical resection of tumors. The company's first target indication is for breast cancer and it is aiming for a US premarket approval in late Q1 of 2019.
Advanced Accelerator Applications (AAA) has hit the headlines with recent rumors of a potential acquisition deal from Novartis. Now that the radiopharmaceutical company has its first therapeutic product approved and ready for commercialization, is AAA really ready to sign the dotted line?
In this edition of Device Week, find out which were the most interesting startups showcased at AdvaMed’s annual Medtech Conference, held at the end of September. Additionally, the last week has seen a surge in acquisition activity – which were the more notable deals that were cut?
On signing a consent decree with the US FDA, Philips is halting manufacture and sales of external defibrillators produced at two facilities until the agency is satisfied the company is complying with current good manufacturing practice requirements. The suspension is expected to impact Philips' EBITA for the fourth quarter 2017 and for 2018.
Home hemodialysis specialist Physidia has appointed a new company president to take the business to grow commercialization of its S3 device.